Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

In the case of CML, some patients treated with imatinib acquire mutations in Bcr-Abl and ultimately progress to an acute phase of the disease. A combination of targeted agents and chemotherapy may ...

Both dasatinib and nilotinib appear to have activity in CML patients with mutations within the abl kinase domain, including in the P-loop, A-loop and catalytic domains. Dasatinib and nilotinib ...

Here’s what the data revealed. The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at ...

Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks. In this review ...

Many important clinical conditions like Down syndrome and chronic myelogenous leukemia result from translocation mutations. A change in chromosome structure and content caused by translocation ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

The previously included indication of adult patients with CML-CP or accelerated-phase CML (CML-AP) harboring the T315I mutation will maintain its reimbursable status on the NRDL. CML is a hematologic ...

In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation. Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a ...

As a novel drug, olverembatinib can effectively target BCR-ABL and a spectrum of BCR-ABL mutants, including the T315I mutation. In November 2021, olverembatinib received its first approval in China, ...